Stereotactic Radiotherapy and Image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Radiosurgery
- Radiotherapy
- Spine Metastases
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: non-randomized trialMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
In this study, Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center of the research group from July 2019 to June 2021 will be collected, as well as their follow-up dat...
In this study, Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center of the research group from July 2019 to June 2021 will be collected, as well as their follow-up data.The metastases were treated with SBRT.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).The metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
Tracking Information
- NCT #
- NCT03963713
- Collaborators
- Mianyang Central Hospital
- Second Hospital of Shanxi Medical University
- Qingdao chengyang hospital
- Qingdao Hiser Medical Group
- Beijing 302 Hospital
- Guangxi Ruikang Hospital
- Third Affiliated Hospital of Guizhou Medical University
- Panjin Liaohe Oilfield Gem Flower Hospital
- Tang-Du Hospital
- Investigators
- Study Chair: Junjie Wang, MD Peking University Third Hospital Study Director: Fei Xu, M Med Peking University Third Hospital Principal Investigator: Hongqing Zhuang, M Med Peking University Third Hospital Principal Investigator: Xiaobo Du, MD Mianyang Central Hospital Principal Investigator: Jie Li, M Med Mianyang Central Hospital Principal Investigator: Xiang Song, M Med Second Hospital of Shanxi Medical University Principal Investigator: Lei Zhang, M Med Second Hospital of Shanxi Medical University Principal Investigator: Jianguo Zhang, M Med Qingdao chengyang people's hospital Principal Investigator: Peng Liu, M Med Qingdao Hiser Medical Group Principal Investigator: Xuezhang Duan, MD Beijing 302 Hospital Principal Investigator: Zuping Lian, MD Guangxi Ruikang Hospital Principal Investigator: Liang Liu, MD Third Affiliated Hospital of Guizhou Medical University Principal Investigator: Longhai Shen, M Med Panjin Liaohe Oilfield Gem Flower Hospital Principal Investigator: Dongjie He, M Med Tang-Du Hospital Principal Investigator: Xuemin Li, MD Peking University Third Hospital Principal Investigator: Yi Chen, MD Peking University Third Hospital
Get Well Soon